IPSEN |
Market Closed -
Other stock markets
|
Pre-market 01:37:01 am | |||
| 112.3 EUR | 0.00% |
|
113.2 | +0.85% |
| Apr. 24 | IPSEN : Better-than-expected Q1; guidance unchanged |  |
| Apr. 24 | Transcript : Ipsen S.A., Q1 2024 Sales/ Trading Statement Call, Apr 24, 2024 |
| Sales 2024 * | 3.45B 3.7B | Sales 2025 * | 3.67B 3.94B | Capitalization | 9.28B 9.95B |
|---|---|---|---|---|---|
| Net income 2024 * | 678M 727M | Net income 2025 * | 708M 760M | EV / Sales 2024 * | 2.52 x |
| Net cash position 2024 * | 585M 628M | Net cash position 2025 * | 1.22B 1.31B | EV / Sales 2025 * | 2.2 x |
| P/E ratio 2024 * |
14.2
x | P/E ratio 2025 * |
13.6
x | Employees | 5,325 |
| Yield 2024 * |
1.05% | Yield 2025 * |
1.07% | Free-Float | 41.52% |
More Fundamentals
* Assessed data
More news
Latest transcript on Ipsen
More press releases
More news
| 1 week | +5.55% | ||
| Current month | +1.81% | ||
| 1 month | +2.93% | ||
| 3 months | +4.17% | ||
| 6 months | -5.07% | ||
| Current year | +4.08% |
1 week
105.30
115.90
1 month
104.60115.90
Current year
99.70115.90
1 year
99.70130.70
3 years
77.00130.70
5 years
34.20130.70
10 years
30.67155.95
| Managers | Title | Age | Since |
|---|---|---|---|
David Loew
CEO | Chief Executive Officer | 57 | 20-06-30 |
| Director of Finance/CFO | 54 | 14-11-02 | |
| Chairman | 66 | 10-11-21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Karen Witts
BRD | Director/Board Member | 61 | 22-01-20 |
Michèle Ollier
BRD | Director/Board Member | 65 | 15-05-26 |
| Chairman | 66 | 10-11-21 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.83% | 2 M€ | +7.83% | ||
| 0.43% | 182 M€ | +7.15% | ||
| 0.31% | 3 M€ | +9.95% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 112.3 | 0.00% | 68,205 |
| 24-04-24 | 112.3 | +0.81% | 109,969 |
| 24-04-23 | 111.4 | -0.98% | 72,843 |
| 24-04-22 | 112.5 | +3.78% | 115,703 |
| 24-04-19 | 108.4 | +1.98% | 61,254 |
Real-time Euronext Paris, April 25, 2024 at 11:35 am EDT
More quotes
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows:
- oncology (75.2%);
- neuroscience (21.1%);
- rare diseases (3.7%).
At the end of 2023, the group had 4 research and development centres located in France, the United Kingdom, the United States and China, and 4 manufacturing sites worldwide.
Net sales are distributed geographically as follows: Europe (40.2%), North America (33.3%) and other (26.5%).
Sector
Pharmaceuticals
Calendar
2024-05-27
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
112.3
EUR
Average target price
124.8
EUR
Spread / Average Target
+11.10%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.08% | 9.91B | |
| +24.17% | 562B | |
| -6.33% | 358B | |
| +19.90% | 322B | |
| +7.95% | 297B | |
| +13.45% | 219B | |
| +6.04% | 199B | |
| -10.51% | 196B | |
| -12.26% | 149B | |
| -6.47% | 146B |
- Stock Market
- Equities
- IPN Stock
